Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia

The efficacy of immunoglobulin replacement therapy (IgRT) has been demonstrated for primary immune deficiency diseases and hematological malignancies such as chronic lymphocytic leukemia (CLL) or multiple myeloma with hypogammaglobulinemia. Clinical development of anti-B cell therapies including a m...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohmoto, Akihiro, Fuji, Shigeo, Shultes, Kendall C., Savani, Bipin N., Einsele, Hermann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017083/
https://www.ncbi.nlm.nih.gov/pubmed/35440805
http://dx.doi.org/10.1038/s41409-022-01680-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017083/
https://www.ncbi.nlm.nih.gov/pubmed/35440805
http://dx.doi.org/10.1038/s41409-022-01680-z

Ejemplares similares